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1 General introduction 
1.1 The Ras superfamily of GTPases 
The Ras superfamily consists of around 167 small GTPase proteins that share the 
ability to bind and hydrolyse GTP (1). Although similar to the alpha subunit of G 
proteins, Ras superfamily proteins function as monomers. The superfamily can be 
divided into seven main families based on sequence homology and functional similarity: 
the Ras, Rho, Ran, Rab, Arf, Miro and RGK families.  
Ras superfamily GTPases share an overall conserved fold, called the G domain, of 
around 20kDa that is involved in nucleotide binding as well as, in most cases, 
conservation of sequences involved in GTP hydrolysis (2). In addition the majority of 
Ras superfamily proteins undergo specific lipid modifications including C-terminal 
addition of farnesyl, geranylgeranyl and palmitoyl moieties (Ras, Rho and Rab familes) 
or N-terminal myristoylation (Arf family) that help localise these small G proteins to 
cellular membranes. Some Ras superfamily members localise to membranes without 
an apparent lipid modification (e.g. Rit, RhoBTB, Miro, Sar1) while Ran and Rerg are 
neither lipid modified nor localised to membranes. 
A direct consequence of these features is the ability of Ras superfamily proteins to 
cycle between an active GTP-bound, and an inactive GDP-bound state. GTP-binding 
induces a conformational change in the protein, in particular at two regions called the 
switch I and II domains, that highly increases affinity of the GTP-bound protein for its 
downstream effectors, thus enabling downstream signalling. Effectors associate mainly 
through a core effector domain that includes the switch I domain. Hydrolysis of GTP 
terminates signalling (3). 
Members of particular Ras subfamilies share similarities not only in sequence but also 
in their function. For example, Ras family proteins have been typically associated with 
the regulation of cellular proliferation, survival and differentiation, Rho family members 
with the regulation of actin dynamics, Rab and Arf proteins with various aspects of 
vesicle trafficking and the smallest subfamily, Ran, with nuclear transport. These are 
not, however, strict divisions and functions are naturally interconnected. Rho family 
members, for example, also play critical roles in the regulation of cell migration, 
differentiation and vesicle transport not only through their roles in the regulation of 
cytoskeletal dynamics but also through the activation of alternative downstream 
signalling pathways (sections 4-5). 
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1.2 Regulation of the Ras superfamily 
Ras proteins regulate a myriad of core signalling functions such as proliferation and 
differentiation, cytoskeletal dynamics and membrane and vesicular trafficking that are 
essential for cell survival and function. Indeed, there are suprisingly few Ras proteins 
when one considers the vast number of cellular functions regulated by these proteins. 
It is important to note that, although the GTP-bound form is the active form for all Ras 
superfamily proteins, the process of GTP/GDP cycling is in itself critical for effective 
downstream signalling. Cycling enables effector dissociation and exchange and 
presents a bottleneck for activation of the multiple, mostly amplifying, downstream 
signalling cascades. Despite being able to bind GTP/GDP and, for the most part, 
possessing low intrinsic GTPase activity, Ras proteins are dependent on regulatory 
proteins to switch them on, off, or to maintain them in an active/inactive state. The main 
Ras regulators are the guanine-nucleotide exchange factors (GEFs), that promote the 
exchange of GDP for GTP, and the GTPase-activating proteins (GAPs) that stimulate 
the hydrolysis rate of GTP (Fig. 1). Guanine nucleotide dissociation inhibitors (GDIs) 
represent an additional class of regulators for the Rho and Rab subfamily and function 
by sequestering the GDP-bound form in the cytosol. These regulators, in particular the 
GEFs and GAPs, are essential for determining the timing, specificity and subcellular 
localization of Ras protein activation as well as the integration of Ras activity with other 
cellular activities and environmental cues. It has been estimated that around 0.5% of 
human genes encode functional GAPs, 60% of which are specific for Rho or Ras 
proteins (section 4-5) (4-6). 
 
Figure 1: Regulation of the 
activity of Ras superfamily 
GTPases. Ras proteins cycle 
between GTP-bound active and 
GDP-bound inactive states. 
Cycling is regulated by guanine-
nucleotide exchange factors 
(GEFs), GTPase-activating 
proteins (GAPs) and guanine 
nucleotide dissociation inhibitors 
(GDIs). Figure by Rosário 
(unpublished). 
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2 Original work 1: Signalling by TC21, a novel Ras family member 
2.1 Introduction 
2.1.1 The Ras family of GTPases 
The Ras family of GTPases has been further subdivided into Ras, Ral, Rit, Rap, and 
Rheb subfamilies. The founding members of this family were the Ras sarcoma 
oncoproteins H-ras and K-ras. These were initially described in the cancer-causing 
viruses Harvey sarcoma virus and Kirsten sarcoma virus, respectively, and later found 
to be also be mutated in human cancer cells (7-14). Subsequently N-Ras was identified 
as the transforming factor in several human cancer cell lines (15-19). Mutation of these 
three genes is one of the most common events in tumourigenesis, and is thought to 
occur in around 30% of all human tumours.  
Two hot spots for Ras oncogenic mutations have been identified around codons 12 and 
61. Glycine 12 is required for the interaction of Ras proteins with GAPs and mutation of 
this site (such as G12V) render Ras insensitive to inactivation. Q61, on the other hand, 
is involved in stabilizing the transition state for GTP hydrolysis and thus mutation of this 
amino acid inhibits the intrinsic GTPase activity of the Ras protein. These residues are 
conserved in most Ras superfamily members and equivalent mutations result in 
constitutively active proteins.  
Most of the other subsequently indentified Ras family proteins do not show transforming 
potential in the conventional NIH3T3 focus-forming assay with the exception of the R-
Ras subfamily of Ras proteins (original work 1). In addition, a few activating mutations 
have by now also been identified in Rho family members (including in Rac1/2, RhoT 
and Cdc42) (20). De-regulation of the expression of Ras superfamily proteins (including 
Ras, Rho, Rab and Arf family members) in cancer cells is more common. 
2.1.2 Ras signalling pathways 
The ERK1/2 MAP kinase pathway is the best characterised signalling pathway 
downstream of Ras proteins. Activation of Ras enables binding to the cytosolic Raf 
family of serine/threonine kinases, thus promoting the translocation of these kinases to 
the plasma membrane. Additional phosphorylation events here promote full Raf kinase 
activation and thus initiate a kinase cascade involving first the dual specificity protein 
kinases MEK1/2 and subsequently the ERK1/2 mitogen-activated protein (MAP) 
kinases. Activated ERK1/2 can phosphorylate multiple cytosolic effectors, and is also 
able to translocate to the nucleus where it can induce trancriptional changes through 
phosphorylation of nuclear targets such as the Ets-family of transcription factors.  
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Other signalling pathways that have by now been shown to be activated downstream of 
Ras proteins include the phosphatidylinositol-3-kinase (PI3K), p38MAPkinase, atypical 
MAP kinase Erk5, phospholipase C gamma (PLC γ) pathways and, through the 
recruitment of different GEFs, a number of other Ras superfamily proteins such as Rac, 
Ral and Rap (4, 21). 
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2.2 Original work 1: Activation of the Ral and phosphatidylinositol 3' kinase 
signalling pathways by the ras-related protein TC21.  
 
Rosario M, Paterson HF, Marshall CJ. 2001. Mol Cell Biol 21:3750-3762. 
https://doi.org/10.1128/MCB.21.11.3750-3762.2001 
TC21 (also called R-Ras2) is a Ras subfamily protein originally identified from an 
expression cDNA library derived from the human ovarian teratocarcinoma cell line 
A2780 (22). The mutation identified in this study, Q72L, is at the equivalent position to 
the hotspot codon 61 in Ras. TC21 shows most similarity to another Ras family 
member, R-Ras and together with M-Ras/R-Ras3 these genes constitute the R-Ras 
subgroup of Ras proteins. At the time of original work 1, another oncogenic mutation 
in TC21 had just been identified in an uterine leiomyosarcoma (23). Indeed, my 
previous research had demonstrated that TC21, like Ras, has transforming activity in 
vitro and that it can also activate the Raf/ ERK1/2 MAP kinase pathway, albeit more 
weakly than the classical Ras genes (24, 25). Activation of this pathway, however, did 
not appear to account for the transforming activity of this protein (26). We therefore, 
searched for other downstream effectors of TC21 that might mediate these cellular 
functions. Original work 1 is the first study to identify Ral and phosphatidylinositol 
3´kinase (PI3K) as dowstream effectors of TC21. In original work 1 we demonstrated 
that oncogenic (V23) TC21 is a powerful activator of class I PI3K through direct 
association with p110, the catalytic subunit of this kinase. Activation of PI3K 
downstream of TC21 induces the membrane translocation and activation of the 
downstream effector Akt and is necessary for TC21-induced morphological changes in 
NIH 3T3 and PC12 rat pheochromocytoma cells. A yeast two-hybrid screen had 
previously identified RalGDS, a GEF for the Ras family member RalA, as a putative 
interactor of TC21 (27), but the significance of this interaction or the function of the Ral 
pathway itself was unknown. We showed for the first time that TC21 could induce the 
translocation to the plasma membrane and thus activation of the cytosolic RalGEF 
family members, RalGDS and the atypical Rlf , in epithelial cells. Furthermore, we 
identified residues T46 and Y51 in TC21 as essential for association with these RalGEF 
family members and demonstrated that interaction of TC21 with RalGEFs results in the 
constitutive hyperactivation of endogenous RalA in NIH 3T3 cells. We also used 
overexpression of the Ral-GTP binding domain (RalBD) of the Ral effector, RalBP1, as 
a tool to selectively inhibit Ral signalling. Using this tool or a dominant negative mutant 
of Ral, we demonstrated that Ral activation downstream of TC21 is essential for TC21-
induced stimulation of DNA synthesis but is dispensible for the morphological 
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alterations in V23 TC21-transformed fibroblast cell lines as well as in human breast and 
uterine cancer cell lines harboring activating mutations in TC21. Furthermore, DNA 
synthesis in these RalBP1 RalBD-expressing cancer cell lines could be restored by 
expression of constitutively active Ral. This was the first demonstration that Ral 
signalling is involved in human tumour cell growth (section 6.1). 
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3 Original work 2: The SHP2 tyrosine phosphatase 
3.1 Introduction 
3.1.1 Activation of Shp2 and downstream signalling 
The PTPN11 gene encodes a non-receptor tyrosine phosphatase called Shp2 (or 
Syp, SH-PTP2, SH-PTP3, PTP1D or PTP2C) that contains two N-terminal SH2 
domains and a C-terminal phosphatase domain. Originally identified in parallel in 
mammals and in Drosophila (and named, Corkscrew, Csw), Shp2 was shown to 
become activated downstream of a subset of receptor tyrosine kinases and to 
promote the downstream activation of the Ras/ERK MAP kinase pathway (28-32). 
Analysis of the crystal structure of Shp2 and biochemical studies have revealed that 
activation of Shp2 is dependent on the release of an intramolecular autoinhibitory 
phosphotyrosine-independent interaction between the N-terminal SH2 domain and 
the phosphatase domain that maintains the protein in a “closed” inactive state. 
Release of this autoinhibitory interaction occurs upon interaction of the Shp2 SH2 
domains with phosphorylated tyrosine residues on activated receptors or associated 
adaptor proteins. Interaction with the receptor complex thus enables substrate 
access to the catalytic site of Shp2 and also localizes this cytosolic protein to the 
receptor complex and thus to the plasma membrane (33, 34). 
 
Figure 2: Activation of Shp2 
An intramolecular phosphotyrosine-independent interaction between the N-terminal SH2 
domain and residues in the phosphatase domain (PTP) keeps Shp2 in an inactive state. 
Higher affinity phosphotyrosine-based interaction of both SH2 domains with tyrosine-
phosphorylated effector proteins release this inhibitory interaction. Figure by Rosário 
(unpublished), based on (35). 
 
The major pathway activated downstream of Shp2 is the Ras/ ERK1/2 MAP kinase 
pathway. Several mechanisms have been suggested to mediate Ras activation 
downstream of Shp2. These include through the recruitment of the adaptor protein 
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Grb2 (36-41), the dephosphorylation of Ras on inhibitory sites (42), the 
dephosphosphorylation of binding sites for negative regulators of Ras such as 
RasGAP on receptors and associated adaptor proteins (43-45), the 
dephosphorylation of the Ras/ERK negative regulator Sprouty (46) and through the 
activation of Src tyrosine kinase either via direct dephosphorylation and thus 
activation of Src proteins or through dephosphorylation of the Src inhibitor Csk (47). 
Other pathways that have been described to be activated downstream of Shp2 
include the Rho family of GTPases (48-50), ROCKII (51), PI3K (52), NF-kB (53) and 
the Jak/Stat signalling pathway (54). Nuclear and mitochondrial functions for Shp2 
have also been proposed (55-58). 
3.1.2 The role of Shp2 in human disease  
Germline mutations in the human PTPN11 gene have been shown to cause Noonan 
(NS) and LEOPARD (Lentigenes, ECG abnormalities, Ocular hypertelorism, 
Pulmonic valvular stenosis, Abnormalities of genitalia, Retardation of growth, and 
Deafness) syndromes (58-61). These are distinct multisymptomatic syndromes that 
are both associated with intellectual disability, different craniofacial and cardiac 
defects and short stature but also show distinct symptoms such as webbed neck, 
skeletal defects and bleeding in NS but not in LEOPARD syndrome. In addition 
somatic mutations in PTPN11 are associated with tumourigenesis. Indeed, PTPN11 
has been found to be mutated in several haematologic malignancies, most notably 
juvenile myelomonocytic leukemia (JMML) (62). Furthermore PTPN11 mutations 
have also been described in a handful of solid tumours including neuroblastomas, 
lung cancer, breast cancer, pilocytic astrocytoma and medulloblastomas (63-69). 
It is estimated that almost 50% of NS patients, 80% of LEOPARD syndrome and 
35% of JMML patients carry mutations in PTPN11 (58; 70-73). Mutations in NS and 
JMML are generally missense and mostly lie either in the N-terminal SH2 domain or 
in the phosphatase domain. These mutations are thought to interfere with the 
autoinhibitory interaction of the N-terminal SH2 and phosphatase domains and hence 
to result in gain of function (GOF) mutants (74, 75). LEOPARD-associated mutations 
were first thought to be loss-of-function (LOF) mutations but subsequent work has 
suggested that they may also possess GOF activity (76). 
The major signalling event underlying these condition appears to be the 
hyperactivation of the Ras/ERK pathway. Mutations in other players of the Ras/ERK 
pathway such as Ras, the serine kinase Raf, the Ras GEF, SOS1 and in and the Ras 
GAP, NF1 have also been described in NS and JMML patients that lack PTPN11 
mutations (58; 77-80). Indeed, NS and LEOPARD are considered to be 
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RASopathies. Other Shp2-regulated pathways that have been associated with these 
conditions include the JAK/Stat pathway (81) and PI3K/Akt pathways (82-84).  
Additionally, animal models have uncovered critical functions for Shp2 in the 
development of several mammalian organs including the heart, CNS, bone and the 
hematopoietic and immune system (section 4.1.1) (58). 
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3.2 Original work 2: Specific inhibitors of the protein tyrosine phosphatase Shp2 
identified by high-throughput docking. 
 
Hellmuth K, Grosskopf S, Lum CT, Wurtele M, Roder N, von Kries JP, Rosario M, Rademann 
J, Birchmeier W. 2008. Proc Natl Acad Sci U S A 105:7275-7280. 
https://doi.org/10.1073/pnas.0710468105 
 
The association of human disease with the aberrant activation of Shp2 has caused 
great interest in the development of a specific inhibitor to Shp2. However, the 
similarity of the catalytic cleft among tyrosine phosphatases presents a challenge for 
the identification of a specific inhibitor. In original work 2 we used a high-thoughput 
in silico screen to identify a small-molecular-weight compound that is specific for 
Shp2. We used available information on the 3D structure of SH2-autoinhibited Shp2 
and of the phosphatase domain of other tyrosine phosphatases together with 
knowledge of the activation mechanism of Shp2 (Fig. 2), to model the open-
configuration state of the Shp2 phosphatase domain. Using this structure, we carried 
out in silico docking of a library of around 2.7 million small molecular weight 
compounds into this catalytic site. This enabled identification of twenty compounds 
that inhibited Shp2 but not the closely related Shp1 phosphatase in an in vitro 
enzymatic assay. Eight of these also blocked signalling by Hepatocyte Growth Factor 
(HGF) in MDCK cells, which is dependent on Shp2 activity (85, 86). The most 
efficient compound, PHPS1 was further studied and several derivatives of this 
compound were generated and tested for specificity and biological activity. The 
predicted binding mechanism of PHPS1 in Shp2 was also confirmed in vitro using 
mutations in Shp2 and by the substitution of amino acids in the related but non-
interacting tyrosine phosphatase PTP1B to those predicted to be relevant for PHPS1 
binding to Shp2. We then used a panel of different biological assays to demonstrate 
that PHPS1 is capable of specifically inhibiting the biological activity and downstream 
signalling of not only wildtype but also a dominant active JMML-associated mutant of 
Shp2 without affecting other parallel signalling pathways or parallel routes to 
activation of the ERK/MAP kinase pathway. Most importantly, we showed that the 
compound is non-cytotoxic, cell-permeable and can inhibit the growth of a panel of 
human tumour cell lines, including very efficiently a lung carcinoma cell line that 
carries an activating mutation in Shp2.  
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4 Original work 3: NOMA-GAP/ARHGAP33: a novel neuronal regulator 
of Shp2 and of the RhoGTPase Cdc42 
4.1 Introduction 
4.1.1 The function of Shp2 during cerebral development 
Noonan syndrome (NS) is associated with mild cognitive impairment and learning 
disability (58, 87). Mice expressing a NS GOF Shp2 mutant in the forebrain show 
defects in exploratory behaviour and memory specificity associated with strongly 
perturbed activity-induced signalling in hippocampal neurons (82).  
Shp2 activation has been shown to be a necessary step downstream of several 
receptors involved in neuronal differentiation and neocortical development. These 
include the fibrobast growth factor receptors (FGFRs) and the Trk family of 
neurotrophin receptors (58). Mutation of the Shp2 binding sites in FRS2 alpha, an 
adaptor protein that can mediate recruitment and activation of Shp2 downstream of 
both of these receptors (88, 89), disturbs neuronal progenitor division and thus 
development of the neocortex in mice (90). The proliferation of neuronal progenitors 
is also disturbed upon conditional knockout of Shp2 in neural progenitors cells using 
the Nestin-Cre recombinase line, and leads to defective neuronal cell fate 
specification and impaired corticogenesis (section 5) (91). Experiments using 
expression of GOF mutants of Shp2 in the neocortex similarily indicated a positive 
role for Shp2 in inducing the neurogenic cell fate in the neocortex (92). Shp2 also 
has pro-neurogenic functions during retinal development (93). In addition, Shp2 has 
critical roles in the mature brain in synaptic plasticity and memory formation as well 
as in the regulation of energy balance and metabolism (94, 95). The signalling 
mechanisms involved in the function of Shp2 in neuronal cells remain poorly 
understood (original work 3). 
4.1.2 Neurotrophin signalling 
Neurotrophins are important regulators of neuronal differentiation, morphology and 
synaptic maturation during brain development as well as of synaptic transmission 
and plasticity in the mature brain. Indeed, defective neurotrophin signalling has been 
associated with a number of human neurological diseases including neuropsychiatric 
diseases such as Autism Spectrum Disorders (ASD), obsessive-compulsive disorder, 
major depression and Schizophrenia, as well as neurodegenerative conditions such 
as Alzheimers and Parkinsons (96, 97). Downstream activation of the MAPK 
cascade, through multiple redundant mechanisms, is a critical and necessary step for 
 34 
neurotrophin function. Shp2 has been shown to be required for the sustained 
activation of the ERK1/2 MAP kinase pathway downstream of neurotrophins (98).  
Another important signalling pathways activated downstream of neurotrophins are 
the Rho family of actin regulators (original work 3) (21). Indeed, Rho GTPases were 
shown to be critical regulators of the various morphological alterations induced by 
neurotrophins during neuronal differentiation or in response to activity, including axon 
outgrowth and dendritic maturation and dendritic tree and spine maturation (99-102). 
4.1.3 The Rho family of GTPases 
The Ras homologous (Rho) family consists of over 20 members that have been 
divided into 8 subgroups based on amino acid similarity (Fig. 3). The best studied 
members are RhoA, Rac1 and Cdc42. Like other Ras proteins, classical 
RhoGTPases act as small molecular switches by cycling between active GTP-bound 
and inactive GDP-bound states. Specificity in the timing, subcellular location and 
kinetics of signalling is thought to be achieved through the differential action and 
properties of Rho regulators, in particular GEFs and GAPs, respectively encoded by 
the ARHGEF and ARHGAP families of genes, which far outnumber the Rho proteins 
themselves.  
 
Figure 3: Phlyogenetic tree of the mammalian RhoGTPases 
The names of the Rho subfamilies are shown next to the grouped members. RhoGTPases 
with known expression in the developing cerebral cortex are underlined (103). Figure by 
Rosário (unpublished), based on (104). 
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RhoGTPases are best known for their ability to direct actin dynamics and thereby 
regulate the cytoskeletal structure. Activation of RhoA is associated with the 
assembly of contractile actin:myosin filaments while Rac1 and Cdc42 both promote 
peripheral actin polymerization and respectively induce the formation of lamellipodia 
and filopodia. Critical for these functions is the activation of two actin polymerization 
factors: the Arp2/3 complex downstream of Rac and Cdc42 and the Formins 
downstream of Rho (105). 
In addition, RhoGTPases regulate several signalling cascades that result in changes 
in gene expression, enzymatic activity and the regulation of microtubule dynamics. 
RhoGTPases are thereby essential regulators of various essential cellular functions 
such as cell proliferation, differentiation, survival, morphology, polarity and movement 
(105, 106). Unsurprisingly, germ line deletion of Rac1 or Cdc42 leads to very early 
embryonic lethality associated with severe morphological defects and cell death 
(107). A large number of tissue-specific deletions in different Rho proteins have since 
been generated that underscore the critical importance of these GTPases for the 
development and function of most tissues analysed (section 5.1.3) (108). 
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4.2  Original work 3: NOMA-GAP/ARHGAP33: The neurite outgrowth 
multiadaptor RhoGAP, NOMA-GAP, regulates neurite extension through SHP2 
and Cdc42. 
 
Rosario M, Franke R, Bednarski C, Birchmeier W. 2007. J Cell Biol 178:503-516. 
https://doi.org/10.1083/jcb.200609146 
 
Original work 3 describes the first identification and characterisation of a novel 
neuron-specific RhoGAP and multiadaptor protein, NOMA-GAP encoded by the 
ARHGAP33 gene (Fig. 4; original works 4 and 5). We identified and cloned NOMA-
GAP through two different routes: by screening expression profile data of E12-E14 
mouse spinal cords and DRGs for sequences predicted to encode GAPs or GEFs for 
Rho family GTPases and by cross-referencing this data to a modified yeast two-
hybrid screen in a human brain cDNA library for novel protein interactors of Shp2. 
Original work 3 also describes the first full-length sequence of PX-RICS encoded by 
the ARHGAP32 gene (other names used for partial sequences, include, RICS, GC-
GAP or GRIT) (109-111). Both NOMA-GAP/ARHGAP33 and PX-RICS/ARHGAP32 
possess an N-terminal Phox (PX)-like domain, a src-homology domain 3 (SH3), a 
RhoGAP domain specific for Cdc42 and a large divergent tyrosine and serine-rich C-
terminus. Given the homology between these proteins in the N-terminal domain-
containing half, we proposed that PX-RICS/ARHGAP32 and NOMA-
GAP/ARHGAP33 form a subfamily of Rho GAPs. This is now accepted (112).  
NOMA-GAP expression during development is restricted to neuronal tissue. Using 
siRNA to downregulate NOMA-GAP expression in the neuronal precursor PC12 
phaechromocytoma cell line and through overexpression of NOMA-GAP in the 
developing chick spinal cord, we showed that NOMA-GAP is essential for NGF-
induced neuronal differentiation and, when overexpressed, is sufficient to induce 
neuronal differentiation in different systems. Furthermore, we showed that NOMA-
GAP directly associates with the NGF receptor, TrkA, and is a constitutive 
component of this receptor complex. Neurotrophin activation leads to the 
phosphorylation of NOMA-GAP/ARHGAP33 on multiple tyrosine residues, two of 
which act as binding and thus activation sites for Shp2 (Fig. 2 and 4). 
Phosphorylation of NOMA-GAP/ARHGAP33 also enables the recruitment of other 
downstream signalling molecules such as the small adaptor proteins and MAP 
kinase activators, Shc and Grb2. Using point mutations in the binding sites for these 
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different downstream effectors, we demonstrated that Shp2-binding is essential for 
NOMA-GAP-induced neuronal differentiation. Moreover, we showed that activation of 
Shp2 downstream of NOMA-GAP and TrkA leads to the sustained activation of the 
atypical MAP kinase, ERK5. In addition, we demonstrated that NOMA-
GAP/ARHGAP33 possesses GAP activity against the Rho family member, Cdc42, 
and is involved in restricting Cdc42 activation and downstream signalling following 
NGF stimulation. Finally, we showed that the GAP activity of NOMA-GAP is also 




Figure 4: Signalling by NOMA-GAP downstream of the neurotrophin receptor, TrkA.  
NOMA-GAP is constitutively associated with the neurotrophin receptor TrkA and becomes 
heavily phosphorylated following receptor activation. This enables recruitment of multiple 
downstream signalling effectors including Shp2, Grb2 and Shc. Both the Shp2 binding site 
and RhoGAP activity are essential for NOMA-GAP and NGF-induced of neurite outgrowth. 
Figure by Rosário (unpublished). 
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5 Original works 4 and 5: the role of NOMA-GAP/ARHGAP33 and the 
RhoGTPase Cdc42 in the development of the cerebral neocortex.  
5.1 Introduction:  
5.1.1 Development of the cerebral neocortex 
The human neocortex is a complex six-layered structure responsible for directing 
higher order brain functions including cognition, advanced motor functions, language, 
social interactions and sensory perception. These functions depend on the correct 
development of two main populations of neurons, the inhibitory GABAergic 
interneurons that are involved in local circuitry and the more abundant excitatory 
projection or pyramidal neurons that extend axons to more distant intracortical, 
subcortical and subcerebral targets (113, 114). Interneurons are born laterally in the 
medial and caudal ganglionic eminences and must migrate tangentially to reach the 
cortex. The pyramidal neurons that occupy the different cortical layers possess 
distinct molecular characteristics, functions and connectivity. They are however, all 
generated by tightly-timed, sequential divisions of progenitor cells found in the 
ventricular and subventricular zones (VZ/SVZ) that overlie the lateral ventricles of the 
dorsal telencephalon (115). This process occurs in an inside-out manner so that 
earlier born neurons occupy the deepest cortical layers while later born neurons must 
undergo radial migration past these earlier born neurons to settle in more superficial 
layers. Newly-born neurons have been described to go through four steps during this 
migratory process: first the acquistion of a bipolar morphology and movement to the 
SVZ, secondly an approximately 24h pause in migration and acquisition of a dynamic 
multipolar morphology, thirdly the extension of a leading process and cellular 
movement towards the ventricle and finally reaquisition of bipolar morphology, 
reversal of polarity and resumption of migration towards the cortical plate (116). 
Migration into the cortical plate occurs along the parallel radial fibers that serve as 
the attachment of radial glia, a progenitor cell type, to the pial surface (Fig. 5) (114). 
Axon extension and determination likely occurs upon cellular contact with the 
ventricle, before start of the migratory stage, and continues during migration (116). 
Formation of the dendritic tree, the highly branched structure that acts as the site of 
information input to the neuron, is suppressed during these early stages and during 
migration and only starts after the neuron has reached its correct position in the 
cortical plate. The mechanism of suppression of dendritic development during 
neuronal differentiation in the neocortex was first addressed in original work 4 
(section 5.2).  
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Upon detachment from the radial fibres, the migratory leading process of the neuron 
extends, contacts the pia and branches to form the apical dendrite. At the same time 
basal dendrites extend and branch from the base of the neuronal soma. The 
branched dendritic tree subsequently undergoes further maturation and dendritic 
spines, the sites of synaptic contact, form along the dendrites. This enables activity-
dependent remodelling of the dendritic tree leading to pruning of some dendrites and 
the strengthening of others (117). Thus, unlike axon determination and outgrowth, 
dendritic tree branching and maturation occurs mainly in the postnatal period and is 
only completed upon adulthood. During adulthood the dendritic tree is mostly stable. 
Dendritic spines, on the other hand, can be dynamically remodelled throughout the 
life of the neuron (118).  
 
Figure 5: Neuronal differentiation during mammalian neocortical development 
In the mammalian neocortex, neurons (green) arise from the asymmetric division of 
progenitor cells (grey) in the ventricular and subventricular zones (VZ/SVZ). The neuron must 
undergo dramatic morphological changes until it has reached its final laminar position in the 
neocortex, differentiated fully and established synaptic contact. Dendritic tree and axon 
morphology are relatively stable in the mature neuron. Dendritic spines, however, are 
continuously remodelled in response to activity and environmental cues in the mature neuron 
requiring dynamic regulation of the cytoskeleton throughout the life of the neuron. Figure by 
Rosário (unpublished). 
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5.1.2 Studying the role of RhoGTPases 
Many of the cellular functions of RhoGTPases have been investigated using 
dominant negative and constitutively active mutants of these GTPases (original 
work 3). Constitutively active mutants contain mutations in sites originally identified 
as hotspot oncogenic mutations in Ras proteins (section 2) and possess a slower 
rate of GTP hydrolysis together with a faster intrinsic GTP/GDP exchange. Dominant 
negative mutants such as S17N, were generated based on equivalent mutations in 
Ras proteins and function by sequestering upstream GEFs, thus preventing 
activation of endogenous Rho proteins (119-122). Given that many GEFs can act on 
multiple Rho proteins, these mutants can affect the activation of multiple Rho 
proteins. Bacterial C3-like ADP-ribosyltransferases that preferentially modify and 
inhibit Rho A, B and C have also been used to examine the function of RhoGTPases 
(123).  
More recently, genetical engineering of mice and the generation of tissue-specific 
deletions of genes encoding Rho proteins and their regulators, has provided an 
alternative and powerful tool for the analysis of the role of these proteins and their 
regulators in normal physiology and during embryonic development (Table 1; 
original work 4). An additional technique that has enabled in vivo analysis of the 
function of RhoGTPases and their regulators is in utero electroporation. Here DNA 
constructs, for example overexpression or downregulation constructs, are injected 
into the lateral ventricles of mouse embryos in utero and are taken up by the 
neuronal progenitor cells lining the ventricle walls following a short electrical pulse 
applied across the developing neocortex. The embryos are allowed to develop 
normally in utero so that the constructs are passed onto all the neurons born from 
these modified progenitors after the time of electroporation (original works 4 and 5) 
(124). 
5.1.3 RhoGTPases and their GAPs in neuronal development and disease 
Neuronal differentiation involves dramatic morphological changes (Fig. 5) which are 
dependent on precisely controlled and dynamic alterations to the cellular 
cytoskeleton. In vitro studies have shown that RhoGTPases play central roles in 
most neuronal functions including during early neuronal differentiation steps such as 
neuritogenesis and the acquisition of polarity, as well as during axon formation and 
guidance, during the development and maturation of the dendritic tree and during 
synaptic transmission (section 4) (125). Furthermore, in vivo studies using Cre-
mediated deletion of floxed Cdc42, Rac1 or RhoA alleles in the mouse brain have 
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emphasized the critical importance of these proteins for neuronal development and 
function (Table 1).  
 
 
Table 1: Summary of the phenotypes observed upon neuronal-specific deletion of the 
RhoGTPases RhoA, Rac1 or Cdc42.  
Several cre lines have been used to study the role of RhoGTPases during cerebral 
development. The Foxg1-Cre line is active in early forebrain cells (136), the Emx1-cre in the 
dorsal telencephalon (137) and the Nestin-cre in CNS progenitor cells including radial glia. 
Table by Rosário (unpublished), based on (108).  
Rac1 
Mouse Cre Line Phenotype 
Foxg1-Cre  
 
Embyonic lethal (late), microcephaly, defects in all commissures and 
projections, cortical laminar disorganisation including cobblestone 
lisencephaly associated with defects in radial glial attachment, survival and 
differentiation (126-128). 
Emx1-Cre  Absence of the corpus callosum and anterior commissure (129).  
Nestin-Cre  Early postnatal lethal, hydrocephalus and cerebellar defects (130). 
Cdc42 
Mouse Cre Line Phenotype 
Foxg1-Cre  
 
Progenitor cells in the neuroepithelium show defects in cell polarity and 
adhesion that may underly the observed holoprosencephaly and thicker 
neuroepithelium (131).  
Emx1-Cre  
 
Neuronal progenitor cells show defects in cell polarity and adherens 
junctions. Increased cortical thickness associated with premature 
neurogenesis and increased number of intermediate progenitors (132). 
Nestin-Cre  Lethal at birth. Loss of axonal tracks and defective growth cones (133). 
RhoA 
Mouse Cre Line Phenotype 
Foxg1-Cre  
 
Enlarged forebrain, exencephaly-like protrusions. Proliferation and cell 
polarity defects (134). 
Emx1-Cre  
 
Megalencephaly associated with increased proliferation, subcortical band 
heterotopia and cobblestone lisencephally associated with defective radial 
glial fibres (135). 
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While mutation of these critical RhoGTPases has not been reported in human 
neurological disease, mutations of genes encoding GEFs and GAPs for 
RhoGTPases have been increasingly identified in association with human 
neurological conditions in particular with intellectual disability and neuropsychiatric 
conditions (138). These include the Rho GAPs oligophrenin-1/ARHGAP41(139) and 
MEGAP/srGAP3/ARHGAP14 (140) as well as the Rho GEFs ARHGEF6 (141) and 
FGD1 (142) all of which have been linked to intellectual disability in humans. Many 
more RhoGTPase regulators have been identified in numerous screens for human 
neurodevelopmental disease-associated single nucleotide polymorphisms (SNPs) 
and copy-number variations (CNVs), but remain further uncharacterised. 
GEFs and GAPs are generally large proteins containing multiple additional protein 
and lipid domains that enable the integration of RhoGTPase regulation with other 
signalling cascades. Of the 70 mammalian Rho GAPs identified so far, we have 
estimated that 50 are expressed in the brain, reflecting the importance of tight 
regulation of RhoGTPases in neuronal cells. Their association with neurological 
disease has heightenened interest in these signalling molecules and the function of 
some Rho GAPs has been analysed in vitro or in vivo using mouse models (original 
work 4 and 5) (103). The emerging picture is that Rho GAPs are critical regulators of 
in vivo neuronal differentiation which direct distinct cellular events or cell types during 
the formation of the brain. 
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5.2 Original work 4: Neocortical dendritic complexity is controlled during 
development by NOMA-GAP-dependent inhibition of Cdc42 and activation of 
cofilin. 
 
Rosario M, Schuster S, Juttner R, Parthasarathy S, Tarabykin V, Birchmeier W. 2012. Genes 
& Dev 26:1743-1757. 
https://doi.org/10.1101/gad.191593.112 
 
In original work 4 we addressed the in vivo function of NOMA-GAP in the mouse 
during development. We inserted the LacZ gene into the ARHGAP33 locus, thus 
disrupting expression of NOMA-GAP. Beta-galactosidase reporter activity in these 
mice is therefore under the control of the endogenous NOMA-GAP promoter. Similar 
to what we observed using in situ hybridisation, beta-galactosidase activity indicates 
that NOMA-GAP is principally expressed in neuronal tissue. In the neocortex, 
NOMA-GAP expression is very strong in all postmitotic layers from around E14.5 but 
absent in the proliferative VZ and SVZ. 
NOMA-GAP-deficient mice are born at the expected Mendelian ratio and are 
indistinguishable from littermate wildtype mice in terms of their size and outward 
appearance. MRI scans showed however, that NOMA-GAP-deficient mice have a 
reduced brain volume associated predominantly with a reduced cortical thickness. 
Overall brain anatomy appears unaltered. Cortical thinning becomes apparent in the 
first postnatal week but there are no changes in total cell number or in the rates of 
cell death or proliferation in the neocortex. The fate specification, migration and final 
laminar position of the different cortical neurons is also unaltered. Original work 4 
demonstrates however, that dendritic arborization, particularly that of upper layer 
neurons, is strongly disturbed in NOMA-GAP-deficient mice and neurons develop 
only very simple, poorly ramified dendritic trees. The number of primary dendrites, 
that is those emerging directly from the soma, is not altered. This indicates that the 
defect is specific to the acquisition of branching complexity. In upper layer neocortical 
neurons, dendritic branching occurs primarily during the first postnatal week in mice, 
after migration of these neurons to their correct laminar position is complete (section 
5.1.1). This process is associated with a decrease in cellular density and a 
corresponding increase in cortical volume. Loss of NOMA-GAP interferes with 
dendritic arborization and thus postnatal cortical volume expansion does not occur 
normally. Original work 4 further shows that NOMA-GAP is a major negative 
regulator of Cdc42 in the developing cortex. Loss of NOMA-GAP is associated with 
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hyperactivation of the Cdc42 and the downstream PAK1/2 signalling pathway in the 
developing neocortex. Indeed, we could restore dendritic branching in NOMA-GAP-
deficient primary neurons in culture by expression of a dominant negative mutant of 
Cdc42 or by re-expression of full-length, but not RhoGAP-defective, NOMA-GAP.  
In original work 4 we also used the technique of in utero electroporation first 
described by Saito et al (143) to selectively modify upper layer neurons in vivo in the 
developing mouse neocortex. Using this technique we showed that hyperactivation of 
Cdc42 in postmitotic neurons, is sufficient to disturb dendritic branching during 
neocortical development.  
To address the molecular mechanism by which Cdc42 activity inhibits dendritic 
arborization, we used an immunoprecipitation (IP)-mass spectrophotometric 
approach to identify changes in phosphorylated proteins in the cortex of NOMA-GAP-
deficient embryos. Through this approach we found that loss of NOMA-GAP is 
associated with increased phosphorylation of the actin polymerization regulator 
cofilin. Phosphorylation of cofilin on serine 3 has been previously shown to be 
catalysed by the kinases LIMK1/2 which can themselves be activated by the Cdc42 
effectors PAK kinases (144-146). PAK1/2 and LIMK1/2 activities are both elevated in 
the developing cortex of NOMA-GAP-deficient mice.  
In order to demonstrate that hyperactivation of Cdc42 is responsible for the 
hyperactivation of PAK/LIMK and the inactivation of cofilin, we used genetic crosses 
between NOMA-GAP-deficient mice, mice carrying a floxed Cdc42 allele (147) and 
mice expressing cre recombinase from the Nex1 cortical postmitotic promoter (148) 
to lower the levels of Cdc42 protein in NOMA-GAP-deficient neurons in vivo (N-cdc-
cre line). Heterozygous deletion of Cdc42 in these mice, restores PAK1/2 and 
LIMK1/2 activity levels as well as cofilin serine 3 phosphorylation levels to those 
observed in wildtype mice. This indicates that hyperactivation of Cdc42 upon loss of 
NOMA-GAP is responsible for the downstream elevated activation of PAK1/2 and 
LIMK1/2 and hyperphosphorylation of cofilin (Fig. 6). Phosphorylation of cofilin on 
serine 3 inhibits the ability of this protein to interact with G or F-actin, thus 
inactivating it (149). 
Heterozygous deletion of Cdc42 in NOMA-GAP deficient mice through this approach 





Figure 6: Cdc42-regulated signalling downstream of NOMA-GAP in the developing 
neocortex. Activation of Cdc42 (conversion to the GTP bound form) initiates a kinase 
cascade involving the activation of the kinases PAK1/2 and LIMK that results in the 
phosphorylation on serine 3 and consequent inactivation of cofilin. NOMA-GAP counteracts 
this pathway by direct inactivation of Cdc42. Figure by Rosário (unpublished). 
 
Finally, we used in utero electroporation of an active mutant of cofilin (S3A) into the 
developing neocortex of NOMA-GAP-deficient mice to address the role of cofilin 
downstream of NOMA-GAP. In vivo expression of S3A cofilin restored the complexity 
of the neuronal dendritic tree in NOMA-GAP-deficient animals, indicating that positive 
regulation of cofilin downstream of NOMA-GAP is essential for the development of 
this important neuronal structure. 
Original work 4 was the first study to establish the role of Cdc42 and downstream 
signalling in the suppression of dendritic branching during the early migratory stage 
of neuronal differentiation and to provide a mechanism for how this suppression is 
relieved upon completion of migration (section 6.3.2).  
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5.3 Original work 5: NOMA-GAP/ARHGAP33 regulates synapse development and 
autistic-like behavior in the mouse. 
 
Schuster S, Rivalan M, Strauss U, Stoenica L, Trimbuch T, Rademacher N, Parthasarathy S, 




Original work 5 addresses the role of NOMA-GAP and Cdc42 signalling during the 
formation of dendritic spines and the establishment of connectivity in the mouse 
neocortex as well as the consequences of loss of NOMA-GAP/ARHGAP33 for 
mouse behaviour.  
NOMA-GAP is found in small vesicles along the dendritic shaft and in large 
accumulations at the heads of spines where it colocalizes with postsynaptic proteins 
suggesting that it may have a function in the development and/or function of the 
dendritic spine. Indeed, orginal work 5 shows that loss of NOMA-GAP in the mouse 
is associated with neocortical neurons that possess dendritic spines with longer 
necks, an indication of immaturity. These neurons also form fewer synapses in 
culture. In line with these observations, we observed that the electrophysiological 
properties of these neurons in acute slices are strongly altered. Interestingly, we 
could restore dendritic spine morphology in vivo by re-expression of full length 
NOMA-GAP by in utero electroporation in the developing mouse neocortex, 
indicating that this is a cell intrinsic defect. Surprisingly however, expression of a 
mutant of NOMA-GAP that lacks the RhoGAP domain in vivo also restored spine 
morphology suggesting that the RhoGAP activity of NOMA-GAP is dispensible for 
the regulation of spine development. We confirmed this by analysing the N-cdc-cre 
mouse line where one copy of the Cdc42 is postmitotically deleted in neocortical 
neurons deficient in NOMA-GAP. Lowering the levels of Cdc42 expression through 
this approach however, did not improve spine morphology or synaptic transmission, 
although the same manipulation is sufficient to restore dendritic branching in these 
mice (original work 4).  
These results suggest that NOMA-GAP exerts its effects on spine morphology 
through a pathway other than Cdc42. Original work 5 shows that NOMA-GAP also 
directly interacts with several members of the MAGUK family of postsynaptic scaffold 
proteins, including PSD-95. Furthermore, we demonstrated that correct subcellular 
localization and phosphorylation of PSD-95 is dependent on the expression of 
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NOMA-GAP. Loss of NOMA-GAP is associated with the hyperphosphorylation of 
PSD-95 on the regulatory serine 295, and relocation of PSD-95 away from the spine 
head and into the dendritic shaft. Interestingly, association with PSD-95 appears to 
negatively regulate the Cdc42 GAP activity of NOMA-GAP. 
Surface expression of the AMPA receptor subunit GluR1 is also dependent on 
expression of NOMA-GAP as shown both by immunofluorescent and surface 
biotinylation studies. The AMPA receptor is an ionotropic transmembrane 
heterotetrameric glutamate receptor that is responsible for most of the fast excitatory 
synaptic transmission in the CNS. Its localization and retention at the dendritic spine 
is indirectly dependent on PSD95 (sections 6.3.3-6.3.4) (150-152). 
Original work 5 also addressed the consequences of loss of NOMA-GAP for animal 
behaviour. Following SHIRPA protocols we first carried out a general 
characterisation of animal health and well-being and then addressed general animal 
behaviour as well as sensory function in a battery of different tests. NOMA-GAP-
deficient mice are indistinguishable from wildtype littermates in terms of their general 
health, sensory perception and gross overall behaviour. However, original work 5 
demonstrates that male NOMA-GAP-deficient mice have strong defects in social 
interaction and recognition. Specifically, male NOMA-GAP-deficient mice spend less 
time interacting with a new mouse, fail to show a preference for spending time with 
another mouse as opposed to an object and fail to distinguish between a familiar and 
an unfamiliar mouse. These alterations in social behaviour were not restored by 
genetically lowering the levels of Cdc42 (N-cdc-cre line).  
Interestingly, we did not see a significant change in the social behaviour of female 
NOMA-GAP-deficient mice. However, NOMA-GAP-deficient, particularly the female, 
mice, showed signs of increased anxiety in a number of the tests undertaken. This 
included increased number of freezing and grooming bouts in a novel environment, 
the building of more complex nests and faster burrowing of foreign objects.  
Increased anxiety and altered social behaviour are characteristics of neuropsychiatric 
disorders such as Autism spectrum disorders and Schizophrenia (section 6.3.5).
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6 Discussion 
6.1 Signalling by the Ras-related protein TC21 
At the time of original work 1, TC21 was a relatively new Ras subfamily protein, that 
exibited transforming potential but that had not been further characterised. Since, 
TC21 has been found to be mutated at the hotspot codons 23/24 and 70/72 
(equivalent to positions 12 and 61 respectively in Ras) in only a small number of 
tumours (153). De-regulation of TC21 expression is much more common and has 
been reported in several human carcinomas including of the oral cavity, esophagus, 
stomach, skin and breast, and in lymphomas and a wide range of CNS tumours 
including glioblastomas, astrocytomas and oligodendrogliomas (153-157). Indeed 
overexpression of TC21 in pre-malignant hyperplasias of the brain has lead to the 
suggestion that this is a key step in triggering transformation in this organ (156).  
Activation of PI3K by TC21, as first identified in original work 1, has since been 
shown to be a critical step for tumourigenesis (158-160). Indeed, in the mammary 
gland, whose normal development is dependent on TC21 activity, TC21 function and 
the downstream activation of PI3K is necessary for both primary tumorigenesis and 
metastasis (161, 162).  
Original work 1 also demonstrated for the first time that TC21 is a powerful activator 
of at the time relatively unknown, Ral pathway and thereby demonstrated a new 
mechanism for crosstalk between different Ras family members. Furthermore, 
original work 1 provided the first demonstration that this pathway was necessary for 
the proliferation of human tumours. Indeed, we showed that activation of the Ral 
pathway although necessary is, by itself, insufficient for tumourigenesis. Subsequent 
work has confirmed these initial observations (163) and established the Ral pathway 
as a critical but not sufficient player in tumourigenesis, in particular downstream of 
Ras signalling. Recently, multiple efforts to selectively target this pathway in human 
cancers have been initiated (164, 165).  
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6.2 Rational design of Shp2 inhibitors 
Hyperactivation of the Ras/ERK MAP kinase pathway has been estimated to be 
involved in the malignant transformation of more than 90% of human cancers. 
Considerable effort has therefore been directed at designing specific inhibitors to 
different components of this cascade (166). In original work 2 we identified and 
characterised a new inhibitor (PHPS1) of Shp2, a tyrosine phosphatase that is 
necessary for the prolonged activation of this pathway. PHPS1 was the first inhibitor 
that could distinguish between Shp2 and the closely related phosphatase, Shp1. This 
was an important criterion. Shp1 is predominantly expressed in the hematopoietic 
system and its deletion or inhibition in these cells can lead to the development of 
myelomonocytic leukemia-like disease and systemic autoimmunity (167). 
PHPS1 is now commercially available from several large pharmaceutical companies 
and has since been used in numerous studies addressing the role of Shp2 in 
different biological contexts including tumourigenesis (42, 168, 169), LEOPARD 
syndrome-associated hypertrophic cardiomyopathy (170) and pulmonary fibrosis 
(171) among others. Several other Shp2 inhibitors have by now been published, but 
PHPS1 remains among the most specific and potent inhibitors for Shp2 available 
(172). 
 92 
6.3 The RhoGAP and multiadaptor protein NOMA-GAP/ARHGAP33 in the 
development of the neocortex and in disease 
6.3.1 Rho GAPs  
Interest in ARHGAPs has increased considerably in recent years due to the 
identification of mutated forms of these genes in association with human 
neurodevelopmental disorders. Most Rho GAPs are still uncharacterised and the 
functional consequences of identified disease-associated SNPs or mutations are 
unknown. Nevertheless, it is acknowledged that a precisely timed activation of the 
different Rho family members is essential for the generation, migration, differentiation 
and cellular functions of neurons (106, 125). Integration of this signalling with 
environmental cues and cellular status is critical to achieve the appropriate cellular 
responses. The large variety and number of protein and lipid interaction and 
regulatory domains present on Rho GAPs enables this precise and integrative 
activation of RhoGTPases and remodelling of the cytoskeleton (Fig. 7) (112).  
Figure 7: Domain structure of the Rho GAPs predicted to be expressed in neuronal 
tissue. The structure of NOMA-GAP is highlighted by a box. Domain prediction using SMART 
v9. Figure assembled by A. Newmann and M. Rosário (unpublished). 
 
Original works 3 to 5 describe the identification of a novel Rho GAP, NOMA-GAP 
(encoded by the ARHGAP33 gene), the characterisation of its signalling and of its 
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cellular functions in the developing neocortex and finally the consequences of loss of 
this protein to animal behaviour. ARHGAP33 encodes, through alternative splicing, 
several proteins of around 137-140kDa that contain a PX (Phox-like) domain, a SH3 
(Src-Homology 3) domain that may be involved in association with receptors, a 
Cdc42-specific RhoGAP domain and a large C-terminal tail rich in phosphorylated 
tyrosine and serine residues (original work 3).  
Many Rho GAPs contain lipid binding motifs that enable localisation to the plasma 
membrane and thus proximity to their targets (Fig. 7). Canonical PX domains have 
been shown to bind phosphoinositides (PIs) (173). Although the PX-like domain of 
NOMA-GAP lacks key residues involved in lipid binding, in vitro association with 
several phosphoinositides has been reported (174). Membrane association may also 
be stabilised through interaction with membrane proteins (orginal work 3, 5) (174, 
175).  
Like other Rho GAPs, NOMA-GAP possesses several protein-interaction domains in 
addition to the required RhoGAP domain. In NOMA-GAP these enable interaction 
with both multiple downstream effectors such as Shp2, Cdc42 and Grb2 but also with 
upstream activators such as the Trk receptors (original work 3). In original work 3 
we showed that NOMA-GAP is constitutively associated with TrkA and that it is 
essential for the activation of signalling downstream of this receptor. Interaction with 
TrkA occurs in a region conserved among other neurotrophin receptors. Indeed, we 
have observed interaction of NOMA-GAP also with TrkB. Interaction of NOMA-GAP 
with TrkB was recently confirmed by another group that further suggested that 
NOMA-GAP is essential for the trafficking and correct subcellular localization of this 
receptor (175, 176). In fact, original work 4, demonstrated that NOMA-GAP is 
localised not only to the plasma membrane but also to intracellular vesicles. 
Furthermore, as demonstrated in original work 5, NOMA-GAP is required for the 
correct surface localisation not only of the neurotrophin receptors but also of the 
AMPA receptors, suggesting a broader role in directing the intracellular transport of 
various dendritic proteins. 
The specificity and catalytic potency of the RhoGAP domain varies among Rho GAP 
proteins. Rho GAPs often show in vitro catalytic activity towards multiple Rho family 
GTPases although in vivo activity is often more restrictive (177). We have shown that 
both in PC12 cells and in the developing mouse neocortex, the major catalytic 
function of NOMA-GAP is the regulation of Cdc42 (original work 3 and 4). In 
accordance, activation of Rac and Rho proteins do not appear to be altered in the 
neocortex upon loss of NOMA-GAP. Furthermore, the reduced complexity of the 
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dendritic tree in these mice can be partially restored by genetic manipulation that 
decrease Cdc42 protein levels (original work 4).  
The GAP activity of NOMA-GAP does not, however, seem to be required for all 
NOMA-GAP–dependent cellular activities. Adipocytes express a variant isoform of 
NOMA-GAP (named TCGAP) that negatively regulates insulin-stimulated GLUT4 
translocation and glucose uptake through a RhoGAP-independent mechanism (174). 
Similarly, we have shown that regulation of dendritic spine morphology by NOMA-
GAP is independent of the RhoGAP domain (orginal work 5). 
6.3.2 NOMA-GAP and the regulation of dendritic branching 
Orginal work 4 uncovered the first molecular mechanism that explains how dendritic 
branching is timed in vivo during formation of the neocortex. When primary neurons 
are placed in culture, dendritic branching and axon extension occur roughly at the 
same time. During neocortical development however, axogenesis is initiated much 
earlier, before the migration of neurons into the cortical plate takes place. Dendritic 
branching, on the other hand, starts only once migration is finished and contact to the 
pial surface is established (178). The mechanisms that prevent dendritic branching 
during the early stages of neuronal differentiation had not been previously 
addressed. Original work 4 indicates that regulation of the RhoGTPase Cdc42 is 
essential for the control of dendritic branching. Activation of Cdc42 has been 
previously shown to play an essential role in maintaining the polarity and thus the 
fate of apical progenitor cells in the VZ of the neocortex (132). In addition, Cdc42 
appears to be required very early during neuronal differentiation for the aquisition of 
polarity and axonogenesis (133, 179, 180). Original work 4 shows, however, that 
continued activation of Cdc42 after these early stages acts as a brake for dendritic 
arborization by leading to the inhibition of the actin-binding molecule, cofilin. 
Prevention of dendritic arborization in these early stages is essential to enable the 
migration of these neurons out of the VZ/SVZ and into their correct laminar position 
in the cortical plate. Upon reaching the cortical plate, however, neurons induce the 
expression of NOMA-GAP which then directly inhibits Cdc42 activity, thus enabling 
the activation of cofilin and initiation of dendritic arborization (Fig. 8). Original work 4 
was the first work to address the postmitotic functions of Cdc42, independently of its 
function in progenitor cells (103). Our observations have stressed the importance of 
addressing each neuronal developmental stage singly and, together with original 
work 5, have highlighted that molecules such as Cdc42 can play distinct roles at 
different timepoints in the differentiation of the neuron. 
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It is still unclear how Cdc42 becomes activated in the neocortex and why upper layer 
neurons are particularly sensitive to loss of the negative Cdc42 regulator, NOMA-
GAP. Upper layer neurons, as the last born neurons, have a longer migratory 
distance to cover than the first-born deeper layer neurons and may for this reason be 
more sensitive to factors that influence their migration or timing of contact with the 
pia. In addition, the developing neocortex expresses a number of other RhoGAPs, 
including PX-RICS/ARHGAP32 which shares close N-terminal homology to NOMA-
GAP (original work 3). These may act as redundant regulators of Cdc42 in deeper 
layer neurons. Although loss of PX-RICS in the mouse does not appear to affect 
neocortical development (181), defects in the extension of primary dendrites have 
been reported following the knockdown of this protein using shRNA in cultured 
neurons (182). In addition, Cdc42 may become more strongly activated in upper 
layer neurons following stimulation of these neurons from pial/upper layer-derived 
diffusible factors such as Reelin and Semaphorin 3A, both of which have been 
shown to regulate actin dynamics through activation of Cdc42 and regulation of 
cofilin (183-188). Finally, upper and deeper layers neurons have unique molecular 
characteristics which may modulate their responses to external stimuli. The 
neurotrophins BDNF and NT-3 have, for example, been shown to exert layer-specific 
effects on the dendritic morphology of neocortical neurons (189). 
Live-imaging studies in hippocampal slices have indicated that neurons first form 
primary dendrites, followed by branches that arise from the sides of the dendritic 
shaft and not from the growing tip (190). These branches start off as short unstable 
actin-rich projections called filopodia that eventually stabilize and extend. Dendritic 
branching therefore requires a dynamic reorganisation of the actin structure in the 
primary dendrite. Cofilin is an actin-severing molecule whose function in creating 
breaks in F-actin may not only act to generate a site for branching to occur but also 
generate a local pool of free actin available for recycling and novel actin 
polymerization. Activation of cofilin in neocortical neurons upon suppression of the 
Cdc42/PAK/LIMK pathway by NOMA-GAP may thus promote branching by 
increasing actin turnover and dynamics (191). In support of our observations, LIMK 
has been shown to stabilize exisiting actin filaments through inhibition of cofilin and 
thereby to inhibit actin dynamics and the growth of new actin filaments (145, 146). 
6.3.3 Spine formation, connectivity and animal behaviour 
Dendritic branching is followed by the formation of specialized cell contact structures, 
the dendritic spines, that enable neurons to receive signals from other neurons. 
Spines are therefore specialized signalling compartments that must be equipped to 
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maintain contact with the axon, to receive and further transmit the signal into the cell 
and to regulate their molecular components in response to the strength, frequency 
and duration of signal transmission as occurs during long-term potentiation (LTP) 
and depression (LTD).  
Spine formation is initiated along dendrite branches through the formation of unstable 
actin-rich filopodia, in a manner similar to the formation of new branches (192). 
Stabilisation of the spine structure occurs upon contact with an incoming axon. 
Further maturation into a mushroom-shaped structure involves the transport of 
postsynaptic proteins into the immature spine and the assembly of the postsynaptic 
density and is accompanied by spine head growth (193).  
Most studies indicate that Cdc42 activity is necessary for the formation of dendritic 
spines (194-196) and that, like other RhoGTPases, it becomes strongly activated at 
the spine head following stimulation (197). Interestingly, unlike other RhoGTPases, 
activation of Cdc42 following stimulation is restricted to the spine head and does not 
diffuse out of the spine head along the neck and into the dendrite (197), suggesting 
the existence of a restricting mechanism. Original work 5 shows that NOMA-GAP, a 
potent inhibitor of Cdc42, is enriched at the postsynaptic site, where it could 
potentially prevent activation of Cdc42. However, original work 5 also shows that 
association of NOMA-GAP with PSD-95, a major postsynaptic scaffold protein, 
inhibits the GAP activity of NOMA-GAP, thereby presumably preventing inhibition of 
Cdc42 at this subcellular location (Fig. 8). 
6.3.4 Regulation of PSD-95 and AMPAR by NOMA-GAP 
Spine maturation and responses to the electrical transmission require the recruitment 
of the glutamatergic AMPARs to the postsynaptic site. This step is dependent on the 
indirect association of AMPARs with PSD-95 through the stargazin family of co-
receptor molecules (150, 152, 198). Loss of PSD-95 is associated with a decrease in 
AMPAR-containing synapses. This has been suggested to result in the synaptic 
defects seen in PSD-95-deficient animals (151, 199). Interestingly, we observe the 
same defects in synaptic transmission namely, a strongly reduced mEPSC frequency 
with no alterations in amplitude in upper layer neurons in acute neocortical slices of 
NOMA-GAP-deficient animals (original work 5). Original work 5 also demonstrates 
that NOMA-GAP directly associates with and regulates PSD-95 (Fig. 8). Aberrant 
phosphorylation and subcellular localization of PSD-95 away from dendritic spine 
heads, as observed upon loss of NOMA-GAP, is expected to result in the 
mislocalisation of AMPARs. Indeed, original work 5 shows that there is a 50% loss 
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in the level of AMPARs at the cell surface of neurons lacking NOMA-GAP. This likely 
explains the aberrant synaptic transmission observed in these animals. 
Many animal models for neuropsychiatric disorders such as ASD, show a 
dysregulation of AMPAR signalling or localisation. Thus, for example surface 
expression of the AMPAR has been shown to be regulated by the ASD and 
Schizophrenia-associated Neurexin-Neuregulin signalling complex (200, 201), the 
Angelmann syndrom-associated E3 ubiquitin ligase Ube3A (202) and the fragile X 
syndrome associated FMRP proteins (203) among others. Disturbances in both 
ionotropic AMPAR and NMDAR signalling as well as in metabotropic glutamate 
signalling have been associated with ASD in humans. These include the elevation of 
serum levels of glutamate in ASD children (204, 205), alterations in the levels of 
AMPA, NMDA and metabotropic glutamate receptors (206) and mutations in several 
NMDAR subunits (207, 208). Several therapeutic approaches aimed at altering 
ionotropic and/or metabotropic glutamatergic neurotransmission have thus been 
developed and are currently been evaluated (208, 209). Interestingly, both NMDAR 
and metabotropic glutamatergic receptor signalling have been shown to regulate the 
trafficking and surface expression of AMPARs (210). 
Figure 8. Regulation of Dendritic arborisation and Spine maturation during neocortical 
development 
During cortical development, newly born neurons (pink) migrate out of the VZ/SVZ and into 
the cortical plate. Migration occurs along radial glia tracks (grey cells). Dendritic arborisation 
is suppressed by Cdc42-mediated inactivation of the actin binding protein cofilin probably 























the expression of ARHGAP33/NOMA-GAP, a multiadaptor protein with RhoGAP activity, 
which suppresses Cdc42 activity, thus enabling cofilin activation. Cofilin activity is essential to 
promote the branching of dendrites (original work 4). Cdc42 activation is enabled during 
maturation of the dendritic spines through the association of NOMA-GAP with PSD-95, which 
inhibits the RhoGAP activity of NOMA-GAP (original work 5). In turn, NOMA-GAP promotes 
the correct subcellular localization and phosphorylation state of PSD-95 and thus spine 
maturation (original work 5). VZ ventricular zone; SVZ subventricular zone; CP cortical plate. 
Figure by Rosário (unpublished). 
6.3.5 Neuropsychiatric disorders and NOMA-GAP/ARHGAP33 
Disorders in dendritic branching and spine formation are associated with cognitive 
alterations including intellectual disability and neuropsychiatric disorders such as 
Autism Spectrum Disorders (ASD) and Schizophrenia (211, 212). The candidate 
molecules identified so far are, like NOMA-GAP, predominantly postsynaptic 
proteins. ARHGAP33/NOMA-GAP-deficient mice show a sexual dimorphic 
behavioural phenotype typically seen in mouse models for neuropsychiatric diseases 
such as ASD and schizophrenia (orginal work 5). Male NOMA-GAP-deficient mice 
have strong defects in social behaviour in standard tests for identifying autism-like 
alterations in the mouse and the female mice show signs of increased anxiety. Both 
genders exhibit normal general behaviour, health and motor and sensory function. 
Importantly, NOMA-GAP-deficient mice show no olfactory deficits, ruling out the 
possibility that their lack of preference for a novel social interaction is due to an 
inability to detect and recognize olfactory cues that are at the basis of all social 
interactions in mice. Given the absence of physical, sensory and motor defects, the 
marked deficits in the preference for the stranger mouse, and the failure to 
distinguish between stranger and familiar mouse, shown by NOMA-GAP-deficient 
male mice can be interpreted as autism-like behaviour (213, 214). Furthermore, 
NOMA-GAP-deficient mice show normal exploration of novel environments, further 
emphasizing the social-nature of the phenotype.  
Anxiety is the most common comorbidity with neuropsychiatric disorders in humans 
(215). Signs of increased animal anxiety, such as aberrant nest building, has also 
been observed in other rodent models for ASD (214). Similarly, NOMA-GAP-deficient 
mice, in particular the females, show signs of increased anxiety. The prevalence of 
anxiety in human patients with neuropsychiatric disorders is also higher in affected 
females. Indeed this leads to a higher initial misdiagnosis of ASD-affected female 
patients with conditions such as anxiety disorder, depression or borderline 
personality disorder (216, 217).  
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Although highly heritable, neuropsychiatric conditions are more frequently associated 
with changes in multiple genes through copy-number variations (CNVs), the 
accumulation of high-risk single-nucleotide polymorphisms (SNPs) or epigenetic 
changes than with single gene mutations. Interestingly, there is a large overlap in the 
genes so far identified in association with ASD, Schizophrenia, intellectual disability 
and epileptic encephalopathy (218, 219). Indeed, recently ARHGAP33 was identified 
as a candidate for severe intellectual disability (220). The mutation identified, 
Val499Met, lies in the RhoGAP domain of NOMA-GAP and is predicted to destabilize 
or deform the GTP-binding site thus lead to the inactivation of this function (220). 
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